Ubiquigent Announces Collaboration with Nanna Therapeutics, a Subsidiary of Astellas
Tuesday, March 12, 2024
Ubiquigent Limited, a company specializing in drug discovery and development, focusing on innovative deubiquitinase (DUB) modulators to address significant medical needs, has announced a partnership with Nanna Therapeutics. This collaboration involves Ubiquigent providing Nanna access to its advanced deubiquitylase (DUB) focused drug discovery platform. The goal is to assist Nanna in developing new therapeutics targeting human disease pathways identified by their research.
DUB enzymes play a vital role in regulating ubiquitination within the ubiquitin-proteasome system (UPS). Dysregulation of DUB activity has been linked to numerous human diseases, highlighting their potential for therapeutic intervention.
Ubiquigent is well-known as a preferred partner for many industry leaders and academic institutions in their drug discovery efforts, particularly in protein degradation, stabilization, and cellular signaling. With extensive experience and a specialized platform, Ubiquigent excels in leveraging DUBs for therapeutic purposes, offering support for the development of DUB inhibitors, DUB-targeting PROTACs, and DUBTACs across various therapeutic domains.
Jason Mundin, CEO of Ubiquigent, expressed enthusiasm about the collaboration, stating, “We are excited to embark on this latest partnership and eager to assist the talented team at Nanna Therapeutics. Our platform was designed to aid those seeking to modulate DUB activity for therapeutic gains and has earned the trust of numerous global partners, including Nanna Therapeutics.”
Source: businesswire.com
